Customize your JAMA Network experience by selecting one or more topics from the list below.
Wiegman A, Hutten BA, de Groot E, et al. Efficacy and Safety of Statin Therapy in Children With Familial HypercholesterolemiaA Randomized Controlled Trial. JAMA. 2004;292(3):331–337. doi:10.1001/jama.292.3.331
Context Children with familial hypercholesterolemia have endothelial dysfunction
and increased carotid intima-media thickness (IMT), which herald the premature
atherosclerotic disease they develop later in life. Although intervention
therapy in the causal pathway of this disorder has been available for more
than a decade, the long-term efficacy and safety of cholesterol-lowering medication
have not been evaluated in children.
Objective To determine the 2-year efficacy and safety of pravastatin therapy in
children with familial hypercholesterolemia.
Design Randomized, double-blind, placebo-controlled trial that recruited children
between December 7, 1997, and October 4, 1999, and followed them up for 2
Setting and Participants Two hundred fourteen children with familial hypercholesterolemia, aged
8 to 18 years and recruited from an academic medical referral center in the
Intervention After initiation of a fat-restricted diet and encouragement of regular
physical activity, children were randomly assigned to receive treatment with
pravastatin, 20 to 40 mg/d (n = 106), or a placebo tablet (n = 108).
Main Outcome Measures The primary efficacy outcome was the change from baseline in mean carotid
IMT compared between the 2 groups over 2 years; the principal safety outcomes
were growth, maturation, and hormone level measurements over 2 years as well
as changes in muscle and liver enzyme levels.
Results Compared with baseline, carotid IMT showed a trend toward regression
with pravastatin (mean [SD], −0.010 [0.048] mm; P = .049), whereas a trend toward progression was observed in the placebo
group (mean [SD], +0.005 [0.044] mm; P = .28). The
mean (SD) change in IMT compared between the 2 groups (0.014 [0.046] mm) was
significant (P = .02). Also, pravastatin significantly
reduced mean low-density lipoprotein cholesterol levels compared with placebo
(−24.1% vs +0.3%, respectively; P<.001).
No differences were observed for growth, muscle or liver enzymes, endocrine
function parameters, Tanner staging scores, onset of menses, or testicular
volume between the 2 groups.
Conclusion Two years of pravastatin therapy induced a significant regression of
carotid atherosclerosis in children with familial hypercholesterolemia, with
no adverse effects on growth, sexual maturation, hormone levels, or liver
or muscle tissue.
Familial hypercholesterolemia is the paradigm of the established relationship
between increased low-density lipoprotein cholesterol (LDL-C) and cardiovascular
disease.1,2 This monogenic disorder
is characterized by exposure to severely elevated LDL-C levels from birth
onward.3,4 Endothelial function,
measured as flow-mediated dilatation of the brachial artery, is already impaired
in prepubertal children with familial hypercholesterolemia.5 In
addition to these early functional changes, accumulation of LDL-C in children
with familial hypercholesterolemia leads to deterioration of the vascular
morphology and gives rise to increased intima-media thickness (IMT) of the
carotid arteries.6-9 As
a sequel to these observations, myocardial ischemia and coronary artery stenoses
have been documented in young adults with this disorder.10,11 The
sequence of events in untreated children proceeds from endothelial dysfunction
to increased arterial wall thickness and, finally, to clinically important
coronary stenoses, often in a span of less than 3 decades.
On diagnosis, adult familial hypercholesterolemia patients are prescribed
lifelong treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins), but postponing statin treatment until adulthood might allow development
of significant arterial lesions in young familial hypercholesterolemia patients.
Accordingly, early initiation of statin treatment in children with familial
hypercholesterolemia might be advantageous, but unfortunately, studies of
such treatment have so far only addressed short-term tolerability and safety.12-16
Given the effects of statins on endogenous cholesterol biosynthesis,
growth and sexual development might be negatively influenced by long-term
exposure to these drugs in children. We therefore performed a placebo-controlled,
randomized clinical trial with pravastatin in 8- to 18-year-old children with
familial hypercholesterolemia; we used carotid IMT to measure efficacy and
growth and maturation to assess the safety of long-term exposure. Carotid
IMT represents the combined intima and media thickness of the arterial wall,
and numerous studies have shown that this surrogate marker of atherosclerotic
vessel wall change is sensitive to risk intervention and constitutes a reliable
indicator of clinical outcomes.17-19
The study was a prospective, randomized, double-blind, placebo-controlled
trial in children with heterozygous familial hypercholesterolemia (Figure 1). The study recruited children between
December 7, 1997, and October 4, 1999, at the Academic Medical Center, University
of Amsterdam, the Netherlands, and followed them up for 2 years; the last
patient left the study on November 4, 2001. Children were eligible when they
met the following criteria: 1 parent with a definite clinical or molecular
diagnosis of familial hypercholesterolemia; age between 8 and 18 years; after
3 months on fat-restricted diet, 2 fasting samples with LDL-C levels of at
least 155 mg/dL (4.0 mmol/L) (99.6% chance of having an LDL receptor mutation20) and triglyceride levels below 350 mg/dL (4.0 mmol/L);
adequate contraception use in sexually active girls; and no drug treatment
for familial hypercholesterolemia or use of plant sterols. Reasons for exclusion
were homozygous familial hypercholesterolemia, hypothyroidism, and abnormal
levels of muscle or liver enzymes. The institutional review board at the Academic
Medical Center approved the study protocol. Written informed consent was obtained
from all children and their parents.
All children were instructed to continue a fat-restricted diet and to
maintain habitual physical activity during the trial. Seven-day diet histories
were obtained 18 months into the treatment period. Completed menu checklists
were analyzed by a dietitian and compared with Dutch advice standards for
children and adolescents21 and a survey of
Dutch children's and adolescents' habits.22
Consenting children with familial hypercholesterolemia were randomly
assigned to receive either pravastatin or placebo. Randomization was achieved
by a computer-generated sequence in blocks of 8 participants. Children younger
than 14 years of age received half a tablet (equivalent to pravastatin, 20
mg, in the intervention group), whereas those aged 14 years or older received
1 tablet (pravastatin, 40 mg) daily in the evening. Placebo tablets resembled
pravastatin. Study drug compliance was monitored by tablet counting. Children
were evaluated every 6 months for 2 years by a single physician masked to
The primary efficacy outcome of this study was defined as the change
from baseline in mean carotid IMT compared between the pravastatin and placebo
groups at 2 years of follow-up. Mean carotid IMT was defined as the mean IMT
of the right and left common carotid, the carotid bulb, and the internal carotid
far wall segments. For a given segment, IMT was defined as the average of
the right and left IMT measurements. If on either side a segment was missing,
IMT was defined as the value of the remaining segment: if both left- and right-side
values were unavailable, the IMT value was considered missing for that segment,
and in that situation, the mean carotid IMT was also considered missing.
One experienced sonographer (blinded) performed all B-mode ultrasound
examinations. B-mode ultrasound image acquisition for the IMT measurements
was performed at entry and after 1 and 2 years of follow-up. An Acuson 128XP/10v
(Acuson Corp, Mountain View, Calif) ultrasound instrument equipped with a
5-10 MHz L7 (Acuson L7) and Extended Frequency ultrasound system software,
version 7.02 (Acuson Corp) was used. The left and right far walls of the carotid
artery segments were imaged in a standardized magnification (2 × 2 cm).
The sonographer saved a video still image of each segment as a 4:1 compressed
JPEG file (Sony DKR-700P video still image recorder). At the end of the study,
1 image analyst (blinded) batch-read all ultrasound images in a random fashion
regarding both participants and the order of their ultrasound visits. In-house–designed
software (eTrack, version 2.3, W. J. Stok, Department of Physiology, Academic
Medical Center, University of Amsterdam) was used as previously published.23
Blood samples for measurement of lipids and lipoproteins were collected
after at least a 12-hour overnight fast at baseline, 3-month intervals for
the first year, and 6-month intervals the second year. Plasma total cholesterol,
high-density lipoprotein cholesterol, and triglyceride levels were determined
with the use of commercially available kits (Boehringer, Mannheim, Germany).
Levels of LDL-C were calculated using the Friedewald equation.24 Lipoprotein(a)
concentrations were determined with the use of the Apo-Tek enzyme-linked immunosorbent
assay (Organon Teknika, Durham, NC). Mutations in the LDL receptor gene were
detected as previously described.25
To measure deleterious effects on maturation and/or growth, we measured
the levels of sex steroids, gonadotropins, and variables of the pituitary-adrenal
axis at baseline and at 1 and 2 years. Measurements of children's height,
weight, body surface area,26 Tanner staging
(genitals/breasts, pubic and axillary hair), and menarche or testicular volume
were also obtained at the same time points. Body mass index was calculated
as weight in kilograms divided by the square of height in meters. School records
were reviewed for education level and yearly progress. To detect potential
adverse effects on muscle and liver enzymes, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and creatine phosphokinase (CPK) were assessed
at the same time as lipids.
Primary Efficacy Outcome. The sample size for
this study was based on the primary efficacy outcome, change from baseline
to 2-year follow-up in mean carotid IMT compared between the 2 groups. Prior
to the trial, replicate ultrasound measurements were performed in 20 children
with familial hypercholesterolemia and 20 unaffected siblings. The standard
deviation (σ) of the means of the differences of the paired, repeated
combined carotid IMT measurements was 0.045 mm (the σ of the mean for
children with familial hypercholesterolemia and that of their siblings were
similar). A sample size, N, for an effect size, Δ, and the σ were
calculated according to N = 2[(Zα + Zβ)σ/Δ]2.
We set the 2-sided α (type I error) at .05 and the β (type II error)
at .10 (power of 90%). Based on these assumptions, a sample size of approximately
100 children in each group was needed to detect a difference of 0.02 mm in
mean carotid IMT over a 2-year period.
Primary Safety Outcome. We subsequently used
this sample size to calculate which safety outcome differences could be detected.
Height measurements were first transformed to standard deviation scores (SDS)
using the Dutch Child Growth Foundation's growth reference program (Growth
Analyzer 2.0 SP2, version 2.2) to adjust for age and sex. For example, an
SDS of 0 means that the measurement of the individual is equal to the mean
of the reference population of the same age and sex. We calculated the difference
between the SDS at the start of the study and the SDS after 2 years of follow-up
for each child. The sample size of 100 in each group had 90% power to detect
a difference of 0.18 SDS (SD, 0.40) with a 2-sided significance level of .05.
Two expert pediatric endocrinologists considered a difference of 0.25 SDS
to be clinically relevant.
The sample size of 50 boys in each group had 90% power to detect a probability
of 0.68 that a measurement of testicular volume in the pravastatin group is
less than an observation in the placebo group with a 2-sided significance
level of .05. The pediatric endocrinologists considered a probability of 0.7
to be clinically relevant. The power for other safety outcomes was not calculated.
At baseline, mean values between the treatment groups were compared
using a t test; data with a skewed distribution were
first log-transformed. χ2 Tests were applied for comparing
distributions of dichotomous data between the groups. Differences in IMT between
the treatment groups in terms of change from baseline after 2 years were analyzed
with analysis of covariance (ANCOVA), in which the independent variables were
treatment group and baseline IMT. In addition, several multivariate models
were built to explore the effects of age, sex, and interaction terms. In some
cases, more than 1 child per family was included, and consequently, data were
related to a small extent. Therefore, data were also analyzed with linear
regression analysis adjusted for family number using generalized estimating
equations in the GENMOD procedure of SAS. Treatment differences in change
from baseline after 2 years in terms of lipids, lipoproteins, and safety measurements
(hormones, liver and muscle enzymes, height, weight, and menarche or testicular
volume) were analyzed with ANCOVA, with adjustments made for baseline values.
Data with a skewed distribution were first log-transformed. Occurrences of
moderate elevations of AST, ALT, and CPK during 2 years of treatment were
compared by using the Fisher exact test. Furthermore, mixed-model analysis
of variance with (linear) time and treatment effects and their interactions
were used to assess the rates of change in AST, ALT, and CPK during follow-up.
Analyses were interpreted at the 2-sided significance level of .05.
Statistical analyses were computed with SAS software, version 8.02 (SAS Institute
Inc, Cary, NC).
In total, 274 consecutive statin-naive children whose initial LDL-C
levels were at least 155 mg/dL were evaluated (Figure 1). In 44 cases, parents, child, or both declined participation,
and in 9 children, the second LDL-C level was below 155 mg/dL. Seven children
were excluded for homozygous familial hypercholesterolemia (n = 3), hypothyroidism
(n = 1), hypertriglyceridemia (n = 1), or persistently elevated levels of
muscle or liver enzymes (n = 2).
Thus, 214 children (100 boys and 114 girls) were randomized, 106 to
pravastatin and 108 to placebo (Figure 1).
The mean and median age was 13.0 years (range, 8.0-18.5 years). In 205 children
(96%), the diagnosis of familial hypercholesterolemia was confirmed by characterization
of the mutation in the LDL receptor gene. Baseline characteristics were similar
in the 2 groups with respect to age, smoking frequency, systolic and diastolic
blood pressure, sex distribution, and, in girls, menarche (Table 1). Premature cardiovascular disease was present in 34% of
the affected parents (median age, 37 [range, 20-50] years), while 10% of parents
with familial hypercholesterolemia had already died of cardiovascular disease
(median age, 37 [range, 23-45] years).
Ten children (all girls; 5 in the pravastatin and 5 in the placebo group)
discontinued the study prematurely because they withdrew consent. However,
only 3 of them had no 2-year follow-up data (2 children in the pravastatin
group and 1 in the placebo group). The available lipids, IMT, and safety data
were included in the primary efficacy and safety analyses as collected until
discontinuation. At 18 months of treatment, both groups were compliant with
their diets, with better fat intake than found in the survey of habits22 and slightly worse fat intake than the recommended
levels.21 The recommended intake of total fat
for adolescents in the Netherlands is 30%, 10% as saturated fat. The surveyed
Dutch adolescents ate 35% total fat and 15% saturated fat, whereas our study
cohort ingested 32.6% total fat and 12.1% saturated fat.
At baseline, the means of the separate carotid IMT segments as well
as the combined carotid IMT were similar in the pravastatin and placebo groups
(Table 2). At the end of the 2-year
trial, all of the carotid arterial wall segments showed a trend toward attenuation
of IMT in the pravastatin group, while these segments exhibited a trend toward
IMT increase in the placebo group (Figure
2). Hence, the mean combined carotid IMT was attenuated after 2
years of treatment with pravastatin (mean [SD] change in IMT, −0.010
[0.048] mm; P = .049) compared with a trend toward
increase of the mean carotid IMT in the placebo group (mean [SD] change in
IMT, +0.005 [0.044] mm; P = .28) (Table 2). The overall change in carotid IMT (0.014 [0.046] mm) differed
significantly between the 2 groups (P = .02). Multivariate
analyses showed that neither sex nor age significantly influenced these results
(mean [SD] change in IMT, 0.010 [0.066] mm; P value
changed from .02 to .03). When the results were analyzed using generalized
estimating equations, the overall results differed only marginally from the
ANCOVA analysis, but the difference in changes for the common carotid artery
segment between the 2 groups became statistically significant (P value changed from .06 to .04). The difference in the changes in
the mean combined carotid IMT became statistically slightly more pronounced
(P value changed from .02 to .01).
As expected, pravastatin significantly reduced mean LDL-C levels compared
with placebo (−24.1% vs +0.3%; P<.001; absolute
differences are shown in Table 2),
which was maintained over the 2-year study period. High-density lipoprotein
cholesterol, triglyceride, and lipoprotein(a) levels did not change significantly
in pravastatin-treated children.
Compliance with study medication, as assessed by tablet counting, revealed
that 84% of tablets were taken, whereas the mean visit attendance per child
was 95% of all study visits.
At baseline, the education level in the 2 groups was equal (P = .68). During the 2-year treatment, pravastatin had no effect on
academic performance; in both groups, 11 children had to repeat a school year
The height of the children increased similarly in the pravastatin and
the placebo groups (7.9 [5.7] and 7.8 [6.1] cm, respectively). Weight increased
8.0 (5.8) kg in the pravastatin group and 7.8 (5.5) kg in the placebo group.
Therefore, body mass index increased 1.3 (1.6) in the pravastatin group and
1.2 (1.3) in the placebo group. During the trial, 5 girls in the placebo group
started menses at a mean age of 12.3 (1.3) years, whereas 12 girls in the
pravastatin group started menses at a mean age of 12.4 (1.8) years. At the
end of the trial, in both groups, 42 of 57 girls were postmenarchal. During
the 2 years of follow-up, changes in testicular volume and Tanner staging
scores were not different between the groups (Table 3 and Table 4).
All endocrine function parameters at entry and after 2 years were not
significantly different between the pravastatin and placebo groups (Table 3). At the end of the trial, no relevant
differences were observed with respect to changes from baseline for AST, ALT,
or CPK (Table 3). No higher than
3-fold elevation occurred in ALT and elevation of higher than 3-fold AST levels
occurred only twice in the placebo group. A higher than 4-fold elevation in
CPK occurred 4 times in the pravastatin group and 3 times in the placebo group.
There was no difference between the 2 groups with respect to the rate of change
of AST, ALT, or CPK during follow-up. One child had an asymptomatic but extreme
CPK elevation (16 400 U/L) after 168 days of study therapy. Within 1
week after stopping the study regimen, her CPK level decreased to normal levels.
The study regimen was reinstated, and at the end of the trial, the child was
found to have been allocated to placebo.
In this randomized, double-blind, placebo-controlled study, we assessed
the 2-year efficacy and safety of pravastatin therapy in children with familial
hypercholesterolemia. We were able to show that statin treatment improved
the lipoprotein profile toward more physiological levels and we observed regression
of carotid IMT. This shows that the increased arterial wall thickness progression
found in children with familial hypercholesterolemia is reversible. Moreover,
we extensively analyzed possible adverse events and untoward influences on
growth and maturation of the children and none were observed, although some
of our safety outcomes may have been underpowered. Finally, the long-term
tolerability of pravastatin was excellent in these children. Discontinuation
of the study protocol was a rare event and equally distributed between the
active medication and placebo groups. So far, only a few studies have evaluated
statin treatment in children with familial hypercholesterolemia.12-16 These
studies showed promising short-term efficacy and reassuring safety in terms
of changes in hepatic and muscle enzymes. Our results are based on longer
follow-up and broader safety measurements. While a previous study using simvastatin
did show mild changes with 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibition,15 our study showed that levels
of dehydroepiandrosterone sulfate and cortisol were unchanged after 2 years
of pravastatin therapy.
Several methodological aspects of our study require comment. Carotid
IMT progression in the placebo group was less than expected, possibly as a
consequence of strict adherence to a healthy lifestyle, including a strict
diet, frequent physical activity, and a low frequency of cigarette smoking.
Also, we used only a surrogate marker of future vascular disease and could
not assess clinical end points, but solid evidence exists that changes in
arterial wall IMT are predictive of cardiovascular outcome.17-19 To
limit IMT measurement variability, a single ultrasound machine was used, 1
experienced sonographer performed all ultrasonagraphy, and images were analyzed
by a single reader. To reduce variability further, image analysis software
automatically investigated each IMT measurement and accounted for the video
line interpolation of the ultrasound equipment. In addition, the double-blind
design ensured that all study personnel were unaware of treatment allocation.
Nevertheless, our findings cannot be extrapolated to children with an increased
atherosclerotic risk as a result of disorders other than familial hypercholesterolemia.
In children with familial hypercholesterolemia, IMT likely constitutes a strong
marker of future risk because it is part of the pathophysiological pathway
from severe hypercholesterolemia to endothelial dysfunction, early atherosclerosis,
and premature onset of cardiovascular disease. Our IMT findings and the observed
efficacy of pravastatin treatment should therefore be restricted to children
with familial hypercholesterolemia.
Although this trial in children with familial hypercholesterolemia has,
to our knowledge, the most extensive follow-up to date, data on even longer-term
safety and efficacy of statin therapy in children are needed.